| Identification | Back Directory | [Name]
L-Argininamide, L-arginyl-L-arginyl-3-(2-naphthalenyl)-L-alanyl-L-cysteinyl-L-tyrosyl-N5-(aminocarbonyl)-L-ornithyl-L-lysyl-D-lysyl-L-prolyl-L-tyrosyl-L-arginyl-N5-(aminocarbonyl)-L-ornithyl-L-cysteinyl-, cyclic (4→13)-disulfide | [CAS]
368874-31-1 | [Synonyms]
TN-14003
L-Argininamide, L-arginyl-L-arginyl-3-(2-naphthalenyl)-L-alanyl-L-cysteinyl-L-tyrosyl-N5-(aminocarbonyl)-L-ornithyl-L-lysyl-D-lysyl-L-prolyl-L-tyrosyl-L-arginyl-N5-(aminocarbonyl)-L-ornithyl-L-cysteinyl-, cyclic (4→13)-disulfide | [Molecular Formula]
C90 H141 N33 O18 S2 | [MOL File]
368874-31-1.mol | [Molecular Weight]
2037.42 |
| Chemical Properties | Back Directory | [density ]
1.53±0.1 g/cm3(Predicted) | [Sequence]
Arg-Arg-{Ala-(2-Naph)}-Cys-Tyr-{Cit}-Lys-Lys-Pro-Tyr-Arg-{Cit}-Cys-Arg-NH2 (Disulfide bridge: Cys4-Cys13) |
| Hazard Information | Back Directory | [Uses]
TN14003 is a CXCR4 inhibitor. TN14003 has antitumor activity[1]. | [in vivo]
TN14003 (7.5 mg/kg, intraperitoneal injection, 5 days per week) inhibits HER2 tumor growth by reducingangiogenesis and myofibroblast content[1].
| [References]
[1] Lefort S, et al. CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients. Oncogene. 2017 Mar 2;36(9):1211-1222. DOI:10.1038/onc.2016.284 |
|
| Company Name: |
Fuan Bio
|
| Tel: |
15002819872 |
| Website: |
fuanbio.com / www.fuanbio.com |
|